Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Total Non-Current Liabilities (2020 - 2025)

Maxcyte (MXCT) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $33.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 5.3% to $33.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $33.2 million, a 5.3% decrease, with the full-year FY2024 number at $32.9 million, down 8.04% from a year prior.
  • Total Non-Current Liabilities was $33.2 million for Q3 2025 at Maxcyte, up from $28.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $35.8 million in Q4 2023 to a low of $13.1 million in Q3 2021.
  • A 5-year average of $28.8 million and a median of $31.3 million in 2024 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: soared 144.74% in 2022, then dropped 10.1% in 2023.
  • Maxcyte's Total Non-Current Liabilities stood at $20.8 million in 2021, then skyrocketed by 50.99% to $31.4 million in 2022, then rose by 14.22% to $35.8 million in 2023, then dropped by 8.04% to $32.9 million in 2024, then grew by 0.7% to $33.2 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Total Non-Current Liabilities are $33.2 million (Q3 2025), $28.8 million (Q2 2025), and $30.3 million (Q1 2025).